DOCSLIB.ORG

Mouse Card11 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Card11 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Card11 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Card11 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Card11 gene (NCBI Reference Sequence: NM_175362 ; Ensembl: ENSMUSG00000036526 ) is located on Mouse chromosome 5. 25 exons are identified, with the ATG start codon in exon 2 and the TGA stop codon in exon 25 (Transcript: ENSMUST00000085786). Exon 4~5 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Card11 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-57O6 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a targeted null mutation exhibit defects in antigen receptor signalling in both T and B lymphocytes. Exon 4 starts from about 6.38% of the coding region. The knockout of Exon 4~5 will result in frameshift of the gene. The size of intron 3 for 5'-loxP site insertion: 4545 bp, and the size of intron 5 for 3'-loxP site insertion: 3707 bp. The size of effective cKO region: ~2528 bp. The cKO region does not have any other known gene. Page 1 of 7 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 4 5 25 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Card11 Homology arm cKO region loxP site Page 2 of 7 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. It may be difficult to construct this targeting vector. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(9028bp) | A(27.72% 2503) | C(22.09% 1994) | T(24.59% 2220) | G(25.6% 2311) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. Significant high GC-content regions are found. It may be difficult to construct this targeting vector. Page 3 of 7 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr5 - 140908903 140911902 3000 browser details YourSeq 505 1 587 3000 92.8% chr5 - 139937075 139937658 584 browser details YourSeq 504 1 587 3000 93.7% chr7 - 19486078 19943100 457023 browser details YourSeq 500 1 586 3000 93.5% chr7 - 28638606 28884204 245599 browser details YourSeq 500 1 566 3000 94.4% chr7 + 30905424 30905991 568 browser details YourSeq 500 1 587 3000 93.7% chr5 + 144637824 144638459 636 browser details YourSeq 497 1 587 3000 93.1% chr7 + 19908284 19908927 644 browser details YourSeq 496 1 587 3000 92.8% chr7 + 18945663 19351235 405573 browser details YourSeq 495 1 577 3000 94.2% chr7 + 28202654 28706171 503518 browser details YourSeq 495 1 567 3000 94.0% chr5 + 139897995 139898564 570 browser details YourSeq 491 1 577 3000 92.9% chr5 + 137157735 137158312 578 browser details YourSeq 490 1 562 3000 93.8% chr7 - 35765402 36025294 259893 browser details YourSeq 490 1 562 3000 94.6% chr5 + 144637771 144638433 663 browser details YourSeq 489 1 562 3000 93.8% chr7 + 19351229 19908370 557142 browser details YourSeq 488 1 563 3000 94.4% chr7 + 30304342 30305116 775 browser details YourSeq 487 1 562 3000 94.3% chr5 - 134043386 134796960 753575 browser details YourSeq 487 1 561 3000 93.8% chr7 + 34922581 34923142 562 browser details YourSeq 486 1 570 3000 93.8% chr5 - 134043166 134043739 574 browser details YourSeq 485 4 562 3000 93.6% chr7 - 24375384 25111795 736412 browser details YourSeq 485 1 587 3000 92.3% chr5 + 141723545 141724230 686 Note: The 3000 bp section upstream of Exon 4 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr5 - 140903375 140906374 3000 browser details YourSeq 133 2803 3000 3000 93.0% chr12 + 77874268 77874534 267 browser details YourSeq 131 2808 3000 3000 91.9% chr12 + 108029238 108029529 292 browser details YourSeq 129 2809 3000 3000 92.2% chr12 + 109062536 109063003 468 browser details YourSeq 128 2803 2964 3000 95.8% chr11 + 93852302 93852510 209 browser details YourSeq 123 2818 2967 3000 93.7% chr11 + 51385185 51575050 189866 browser details YourSeq 117 2827 2999 3000 94.7% chr12 + 106428620 106428929 310 browser details YourSeq 117 2339 3000 3000 92.2% chr1 + 118822279 119039766 217488 browser details YourSeq 115 2801 2967 3000 90.8% chr14 - 31526640 31526822 183 browser details YourSeq 113 2801 2966 3000 93.9% chr11 + 51575119 51575303 185 browser details YourSeq 107 2818 2965 3000 83.6% chr14 + 111110413 111110548 136 browser details YourSeq 107 2805 2967 3000 84.0% chr10 + 79641293 79641447 155 browser details YourSeq 106 2806 3000 3000 88.7% chr3 - 144109140 144109326 187 browser details YourSeq 104 2808 2963 3000 94.1% chr12 + 109062731 109062986 256 browser details YourSeq 103 2803 2967 3000 85.9% chr11 - 119583216 119583344 129 browser details YourSeq 102 2827 2991 3000 86.4% chr10 + 79641231 79641383 153 browser details YourSeq 98 2807 2947 3000 93.9% chr5 - 112579626 112579797 172 browser details YourSeq 93 2803 2967 3000 81.5% chr13 - 103756200 103756328 129 browser details YourSeq 91 2829 2961 3000 97.0% chr15 + 28039161 28039458 298 browser details YourSeq 87 2803 2956 3000 94.8% chr16 - 11625332 11625560 229 Note: The 3000 bp section downstream of Exon 5 is BLAT searched against the genome. No significant similarity is found. Page 4 of 7 https://www.alphaknockout.com Gene and protein information: Card11 caspase recruitment domain family, member 11 [ Mus musculus (house mouse) ] Gene ID: 108723, updated on 24-Sep-2019 Gene summary Official Symbol Card11 provided by MGI Official Full Name caspase recruitment domain family, member 11 provided by MGI Primary source MGI:MGI:1916978 See related Ensembl:ENSMUSG00000036526 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as BIMP3; CARMA1; 0610008L17Rik; 2410011D02Rik Expression Biased expression in spleen adult (RPKM 26.7), thymus adult (RPKM 15.8) and 6 other tissuesS ee more Orthologs human all Genomic context Location: 5; 5 G2 See Card11 in Genome Data Viewer Exon count: 25 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 5 NC_000071.6 (140872999..141000596, complement) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 5 NC_000071.5 (141348953..141476550, complement) Chromosome 5 - NC_000071.6 Page 5 of 7 https://www.alphaknockout.com Transcript information: This gene has 3 transcripts Gene: Card11 ENSMUSG00000036526 Description caspase recruitment domain family, member 11 [Source:MGI Symbol;Acc:MGI:1916978] Gene Synonyms 0610008L17Rik, 2410011D02Rik, BIMP3, CARMA1 Location Chromosome 5: 140,872,990-141,000,582 reverse strand. GRCm38:CM000998.2 About this gene This gene has 3 transcripts (splice variants), 189 orthologues, 3 paralogues, is a member of 1 Ensembl protein family and is associated with 56 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Card11-201 ENSMUST00000085786.6 4107 1154aa ENSMUSP00000082941.5 Protein coding CCDS51686 Q8CIS0 TSL:1 GENCODE basic APPRIS P1 Card11-202 ENSMUST00000196169.1 1299 No protein - Retained intron - - TSL:1 Card11-203 ENSMUST00000199091.1 1067 No protein - Retained intron - - TSL:1 147.59 kb Forward strand 140.90Mb 140.95Mb 141.00Mb Contigs AC131725.2 > Genes (Comprehensive set... < Card11-201protein coding < Card11-202retained intron < Card11-203retained intron Regulatory Build 140.90Mb 140.95Mb 141.00Mb Reverse strand 147.59 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Transcription Factor Binding Site Gene Legend Protein Coding merged Ensembl/Havana Non-Protein Coding processed transcript Page 6 of 7 https://www.alphaknockout.com Transcript: ENSMUST00000085786 < Card11-201protein coding Reverse strand 127.59 kb ENSMUSP00000082... MobiDB lite Low complexity (Seg) Coiled-coils (Ncoils) Superfamily Death-like domain superfamily PDZ superfamily P-loop containing nucleoside triphosphate hydrolase Pfam CARD domain PROSITE profiles CARD domain PANTHER PTHR14559 Caspase recruitment domain-containing protein 11 Gene3D 1.10.533.10 2.30.42.10 2.30.30.40 3.40.50.300 CDD CARD11, CARD domain cd00992 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend missense variant splice region variant synonymous variant Scale bar 0 100 200 300 400 500 600 700 800 900 1000 1154 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 7 of 7.
Load more

Recommended publications
  • Hypomorphic CARD11 Mutations Associated with Diverse Immunologic Phenotypes with Or Without Atopic Disease
    This is a repository copy of Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/135712/ Version: Accepted Version Article: Dorjbal, B, Stinson, JR, Ma, CA et al. (52 more authors) (2019) Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease. The Journal of Allergy and Clinical Immunology, 143 (4). pp. 1482-1495. ISSN 0091-6749 https://doi.org/10.1016/j.jaci.2018.08.013 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Accepted Manuscript Hypomorphic CARD11 mutations associated with diverse immunologic phenotypes with or without atopic disease Batsukh Dorjbal, PhD, Jeffrey R. Stinson, PhD, Chi A.
    [Show full text]
  • Lymphomagenic CARD11/BCL10/MALT1 Signaling Drives Malignant B-Cell Proliferation Via Cooperative NF-Κb and JNK Activation
    Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation Nathalie Kniesa, Begüm Alankusa, Andre Weilemannb,c, Alexandar Tzankovd, Kristina Brunnera, Tanja Ruffa, Marcus Kremere, Ulrich B. Kellerf, Georg Lenzb,c, and Jürgen Rulanda,g,h,1 aInstitut für Klinische Chemie und Pathobiochemie, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany; bTranslational Oncology, Department of Medicine A, University Hospital Münster, 48149 Münster, Germany; cCells in Motion, Cluster of Excellence EXC 1003, 48149 Münster, Germany; dInstitute of Pathology, University Hospital Basel, 4031 Basel, Switzerland; eInstitut für Pathologie, Klinikum Harlaching, 81545 Munich, Germany; fDepartment of Medicine III, Klinikum Rechts der Isar, Technische Universität München, 81675 Munich, Germany; gGerman Cancer Consortium, 69120 Heidelberg, Germany; and hGerman Center for Infection Research, 81675 München, Germany Edited by Tak W. Mak, The Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, and approved November 12, 2015 (received for review April 16, 2015) The aggressive activated B cell-like subtype of diffuse large B-cell (PI3K) (reviewed in ref. 8). The key link to the IKK complex is lymphoma is characterized by aberrant B-cell receptor (BCR) signal- the scaffolding molecule caspase recruitment domain-containing ing and constitutive nuclear factor kappa-B (NF-κB) activation, which protein 11 (CARD11), which is inactive in resting cells due to an is required for tumor cell survival. BCR-induced NF-κBactivationre- intramolecular inhibitory interaction between its linker region quires caspase recruitment domain-containing protein 11 (CARD11), and its coiled-coil domain (9).
    [Show full text]
  • PRKCQ / PKC-Theta Antibody (Aa640-690) Rabbit Polyclonal Antibody Catalog # ALS16240
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 PRKCQ / PKC-Theta Antibody (aa640-690) Rabbit Polyclonal Antibody Catalog # ALS16240 Specification PRKCQ / PKC-Theta Antibody (aa640-690) - Product Information Application WB, IHC Primary Accession Q04759 Reactivity Human, Mouse, Rat Host Rabbit Clonality Polyclonal Calculated MW 82kDa KDa PRKCQ / PKC-Theta Antibody (aa640-690) - Additional Information Gene ID 5588 Other Names Protein kinase C theta type, 2.7.11.13, Western blot of PKC (N670) pAb in extracts nPKC-theta, PRKCQ, PRKCT from A549 cells. Target/Specificity Human PKC Theta Reconstitution & Storage Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Precautions PRKCQ / PKC-Theta Antibody (aa640-690) is for research use only and not for use in diagnostic or therapeutic procedures. Anti-PRKCQ / PKC-Theta antibody IHC staining of human brain, cerebellum. PRKCQ / PKC-Theta Antibody (aa640-690) - Protein Information PRKCQ / PKC-Theta Antibody (aa640-690) - Name PRKCQ Background Synonyms PRKCT Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent Function serine/threonine-protein kinase that mediates Calcium-independent, phospholipid- and non- redundant functions in T-cell receptor diacylglycerol (DAG)- dependent (TCR) signaling, including T-cells activation, serine/threonine-protein kinase that proliferation, differentiation and survival, by mediates non-redundant functions in T-cell mediating activation of multiple transcription receptor (TCR) signaling, including T-cells factors such as NF-kappa-B, JUN, NFATC1 and activation, proliferation, differentiation and NFATC2. In TCR-CD3/CD28-co-stimulated Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 survival, by mediating activation of multiple T-cells, is required for the activation of transcription factors such as NF-kappa-B, NF-kappa-B and JUN, which in turn are JUN, NFATC1 and NFATC2.
    [Show full text]
  • Defining the Relevant Combinatorial Space of the PKC/CARD-CC Signal Transduction Nodes
    bioRxiv preprint doi: https://doi.org/10.1101/228767; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Defining the relevant combinatorial space of the PKC/CARD-CC signal transduction nodes Jens Staal1,2,*, Yasmine Driege1,2, Mira Haegman1,2, Styliani Iliaki1,2, Domien Vanneste1,2, Inna Affonina1,2, Harald Braun1,2, Rudi Beyaert1,2 1 Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium, 2 VIB-UGent Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, Ghent, Belgium. * corresponding author: [email protected] Running title: PKC/CARD-CC signaling Abbreviations: Bcl10 = B Cell CLL/Lymphoma 10 CARD = Caspase activation and recruitment domain CC = Coiled-coil domain MALT1 = Mucosa-associated lymphoid tissue lymphoma translocation protein 1 PKC = protein kinase C Keywords: Inflammation, cancer, NF-kappaB, paracaspase Conflict of interests: The authors declare no conflict of interest. bioRxiv preprint doi: https://doi.org/10.1101/228767; this version posted May 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Abstract Biological signal transduction typically display a so-called bow-tie or hour glass topology: Multiple receptors lead to multiple cellular responses but the signals all pass through a narrow waist of central signaling nodes.
    [Show full text]
  • Structural Determinants of MALT1 Protease Activity
    doi:10.1016/j.jmb.2012.02.018 J. Mol. Biol. (2012) 419,4–21 Contents lists available at www.sciencedirect.com Journal of Molecular Biology journal homepage: http://ees.elsevier.com.jmb Structural Determinants of MALT1 Protease Activity Christian Wiesmann 1, Lukas Leder 1, Jutta Blank 1, Anna Bernardi 1, Samu Melkko 1, Arnaud Decock 1, Allan D'Arcy 1, Frederic Villard 1, Paulus Erbel 1, Nicola Hughes 1, Felix Freuler 1, Rainer Nikolay 1, Juliano Alves 2, Frederic Bornancin 1 and Martin Renatus 1⁎ 1Novartis Institutes for BioMedical Research, Forum 1, Novartis Campus, CH-4002 Basel, Switzerland 2Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA Received 19 December 2011; The formation of the CBM (CARD11–BCL10–MALT1) complex is pivotal received in revised form for antigen-receptor-mediated activation of the transcription factor NF-κB. 13 February 2012; Signaling is dependent on MALT1 (mucosa-associated lymphoid tissue accepted 15 February 2012 lymphoma translocation protein 1), which not only acts as a scaffolding Available online protein but also possesses proteolytic activity mediated by its caspase-like 23 February 2012 domain. It remained unclear how the CBM activates MALT1. Here, we provide biochemical and structural evidence that MALT1 activation is Edited by M. Guss dependent on its dimerization and show that mutations at the dimer interface abrogate activity in cells. The unliganded protease presents itself in Keywords: a dimeric yet inactive state and undergoes substantial conformational protease; changes upon substrate binding. These structural changes also affect the caspase; conformation of the C-terminal Ig-like domain, a domain that is required for structure; MALT1 activity.
    [Show full text]
  • Molecular Architecture and Regulation of BCL10-MALT1 Filaments
    ARTICLE DOI: 10.1038/s41467-018-06573-8 OPEN Molecular architecture and regulation of BCL10-MALT1 filaments Florian Schlauderer1, Thomas Seeholzer2, Ambroise Desfosses3, Torben Gehring2, Mike Strauss 4, Karl-Peter Hopfner 1, Irina Gutsche3, Daniel Krappmann2 & Katja Lammens1 The CARD11-BCL10-MALT1 (CBM) complex triggers the adaptive immune response in lymphocytes and lymphoma cells. CARD11/CARMA1 acts as a molecular seed inducing 1234567890():,; BCL10 filaments, but the integration of MALT1 and the assembly of a functional CBM complex has remained elusive. Using cryo-EM we solved the helical structure of the BCL10- MALT1 filament. The structural model of the filament core solved at 4.9 Å resolution iden- tified the interface between the N-terminal MALT1 DD and the BCL10 caspase recruitment domain. The C-terminal MALT1 Ig and paracaspase domains protrude from this core to orchestrate binding of mediators and substrates at the filament periphery. Mutagenesis studies support the importance of the identified BCL10-MALT1 interface for CBM complex assembly, MALT1 protease activation and NF-κB signaling in Jurkat and primary CD4 T-cells. Collectively, we present a model for the assembly and architecture of the CBM signaling complex and how it functions as a signaling hub in T-lymphocytes. 1 Gene Center, Ludwig-Maximilians University, Feodor-Lynen-Str. 25, 81377 München, Germany. 2 Research Unit Cellular Signal Integration, Institute of Molecular Toxicology and Pharmacology, Helmholtz-Zentrum München - German Research Center for Environmental Health, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany. 3 University Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale IBS, F-38044 Grenoble, France. 4 Department of Anatomy and Cell Biology, McGill University, Montreal, Canada H3A 0C7.
    [Show full text]
  • Analysis of CARD10 and CARD11 Somatic Mutations in Patients with Ovarian Endometriosis
    ONCOLOGY LETTERS 16: 491-496, 2018 Analysis of CARD10 and CARD11 somatic mutations in patients with ovarian endometriosis YANG ZOU1,2, JIANG-YAN ZHOU1,3, FENG WANG1,2, ZI-YU ZHANG1,2, FA-YING LIU1,2, YONG LUO1,2, JUN TAN1,4, XIN ZENG1, XI-DI WAN1 and OU-PING HUANG1,3 1Key Laboratory of Women's Reproductive Health of Jiangxi Province; 2Central Laboratory; 3Department of Gynecology; 4Reproductive Medicine Center, Jiangxi Provincial Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. China Received October 11, 2017; Accepted March 27, 2018 DOI: 10.3892/ol.2018.8659 Abstract. Endometriosis is a complex and heterogeneous amongst 101 cases of ovarian endometriosis for the first time, pre-malignant inflammatory disease harboring multiple these mutations may serve active roles in the development of gene mutations. Previous studies have suggested that caspase ovarian endometriosis. recruitment domain family member (CARD)10 and CARD11 mutations may exist in endometriosis. In the present study, Introduction a collection of endometriotic lesions and paired peripheral blood from 101 patients with ovarian endometriosis were Endometriosis is a heterogeneous estrogen-dependent chronic obtained, and the entire coding sequences of the CARD10 gynecological disease in women of reproductive age (1-3). The and CARD11 genes were sequenced. Evolutionary conserva- condition is characterized by endometrial tissues ectopically tion analysis and online prediction programs were applied implanting outside the uterine cavity, and is subdivided mainly to analyze the disease-causing potential of the identified into ovarian, peritoneal and deep infiltrating endometriosis mutations. A total of 4 novel somatic mutations were according to the different implant locations (4,5).
    [Show full text]
  • Rare Copy Number Variants in the Genome of Chinese Female Children and Adolescents with Turner Syndrome
    Bioscience Reports (2019) 39 BSR20181305 https://doi.org/10.1042/BSR20181305 Research Article Rare copy number variants in the genome of Chinese female children and adolescents with Turner syndrome Li Li1,*, Qingfeng Li1,*, Qiong Wang2,LiLiu3,RuLi4,HuishuLiu1, Yaojuan He1 and Gendie E. Lash2 1Department of Obstetrics and Gynecology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510160, China; 2Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510160, China; 3Department of Pediatrics Endocrinology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510160, China; 4Prenatal Diagnostic Center, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, Guangdong 510160, China Correspondence: Li Li ([email protected]) or Gendie E. Lash ([email protected]) Turner syndrome (TS) is a congenital disease caused by complete or partial loss of one X chromosome. Low bone mineral status is a major phenotypic characteristic of TS that can not be fully explained by X chromosome loss, suggesting other autosomal-linked mutations may also exist. Therefore, the present study aimed to detect potential genetic mutations in TS through examination of copy number variation (CNV). Seventeen patients with TS and 15 healthy volunteer girls were recruited. Array-based comparative genomic hybridization (a-CGH) was performed on whole blood genomic DNA (gDMA) from the 17 TS patients and 15 healthy volunteer girls to identify potential CNVs. The abnormal CNV of one identified gene (CARD11) was verified by quantitative PCR.
    [Show full text]
  • Intrinsic Plasma Cell Differentiation Defects in B Cell Expansion with Nf-Κb and T Cell Anergy Patient B Cells
    ORIGINAL RESEARCH published: 02 August 2017 doi: 10.3389/fimmu.2017.00913 Intrinsic Plasma Cell Differentiation Defects in B Cell Expansion with NF-κB and T Cell Anergy Patient B Cells Swadhinya Arjunaraja 1, Brent D. Nosé 1, Gauthaman Sukumar 2,3, Nathaniel M. Lott 2,3, Clifton L. Dalgard 2,3 and Andrew L. Snow 1* 1 Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 2 Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States, 3 The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, United States B cell Expansion with NF-κB and T cell Anergy (BENTA) disease is a novel B cell lymph- oproliferative disorder caused by germline, gain-of-function mutations in the lymphocyte Edited by: scaffolding protein CARD11, which drives constitutive NF- B signaling. Despite dramatic Elissa Deenick, κ Garvan Institute of Medical polyclonal expansion of naive and immature B cells, BENTA patients also present with Research, Australia signs of primary immunodeficiency, including markedly reduced percentages of class- Reviewed by: switched/memory B cells and poor humoral responses to certain vaccines. Using purified Vanessa L. Bryant, Walter and Eliza Hall Institute for naive B cells from our BENTA patient cohort, here we show that BENTA B cells exhibit Medical Research, Australia intrinsic defects in B cell differentiation. Despite a profound in vitro survival advantage David Andrew Fulcher, relative to normal donor B cells, BENTA patient B cells were severely impaired in their Australian National University, lo hi Australia ability to differentiate into short-lived IgD CD38 plasmablasts or CD138+ long-lived Julia Ellyard, plasma cells in response to various stimuli.
    [Show full text]
  • Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas
    Published OnlineFirst February 15, 2011; DOI: 10.1158/0008-5472.CAN-10-2525 Cancer Therapeutics, Targets, and Chemical Biology Research Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas Tara L. Naylor1, Huaping Tang1, Boris A. Ratsch2, Andreas Enns2, Alice Loo1, Liqing Chen1, Peter Lenz3, Nigel J. Waters1, Walter Schuler4, Bernd Dorken€ 2, Yung-mae Yao1, Markus Warmuth1, Georg Lenz2, and Frank Stegmeier1 Abstract The activated B-cell–like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) correlates with poor prognosis. The ABC subtype of DLBCL is associated with constitutive activation of the NF-kB pathway, and oncogenic lesions have been identified in its regulators, including CARD11/CARMA1 (caspase recruitment domain-containing protein 11), A20/TNFAIP3, and CD79A/B. In this study, we offer evidence of therapeutic potential for the selective PKC (protein kinase C) inhibitor sotrastaurin (STN) in preclinical models of DLBCL. A significant fraction of ABC DLBCL cell lines exhibited strong sensitivity to STN, and we found that the molecular nature of NF-kB pathway lesions predicted responsiveness. CD79A/B mutations correlated with STN sensitivity, whereas CARD11 mutations rendered ABC DLBCL cell lines insensitive. Growth inhibitory effects of PKC inhibition correlated with NF-kB pathway inhibition and were mediated by induction of G1-phase cell-cycle arrest and/or cell death. We found that STN produced significant antitumor effects in a mouse xenograft model of CD79A/B-mutated DLBCL. Collectively, our findings offer a strong rationale for the clinical evaluation of STN in ABC DLBCL patients who harbor CD79 mutations also illustrating the necessity to stratify DLBCL patients according to their genetic abnormalities.
    [Show full text]
  • Congenital B Cell Lymphocytosis Explained by Novel Germline CARD11 Mutations
    Article Congenital B cell lymphocytosis explained by novel germline CARD11 mutations Andrew L. Snow,1,4 Wenming Xiao,5 Jeffrey R. Stinson,4 Wei Lu,1 Benjamin Chaigne-Delalande,1 Lixin Zheng,1 Stefania Pittaluga,6 Helen F. Matthews,1 Roland Schmitz,7 Sameer Jhavar,7 Stefan Kuchen,8 Lela Kardava,2 Wei Wang,2 Ian T. Lamborn,3 Huie Jing,3 Mark Raffeld,6 Susan Moir,2 Thomas A. Fleisher,9 Louis M. Staudt,7 Helen C. Su,3 and Michael J. Lenardo1 Downloaded from http://rupress.org/jem/article-pdf/209/12/2247/1207150/jem_20120831.pdf by guest on 01 October 2021 1Lymphocyte Molecular Genetics Unit, Laboratory of Immunology; 2Immunopathogenesis Section, Laboratory of Immunoregulation; and 3Laboratory of Host Defenses; National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD 20892 4Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 5Bioinformatics and Molecular Analysis Section, Division of Computational Bioscience, Center for Information Technology, NIH, Bethesda, MD 20892 6Laboratory of Pathology and 7Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892 8Genomics and Immunity Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD 20892 9Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD 20892 Nuclear factor-B (NF-B) controls genes involved in normal lymphocyte functions, but constitutive NF-B activation is often associated with B cell malignancy. Using high- throughput whole transcriptome sequencing, we investigated a unique family with hereditary polyclonal B cell lymphocytosis. We found a novel germline heterozygous missense mutation (E127G) in affected patients in the gene encoding CARD11, a scaffolding protein required for antigen receptor (AgR)–induced NF-B activation in both B and T lymphocytes.
    [Show full text]
  • Structures of Autoinhibited and Polymerized Forms of CARD9 Reveal Mechanisms of CARD9 and CARD11 Activation
    ARTICLE https://doi.org/10.1038/s41467-019-10953-z OPEN Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation Michael J. Holliday 1, Axel Witt1, Alejandro Rodríguez Gama2, Benjamin T. Walters 3, Christopher P. Arthur4, Randal Halfmann2,5, Alexis Rohou 4, Erin C. Dueber1 & Wayne J. Fairbrother 1 1234567890():,; CARD9 and CARD11 drive immune cell activation by nucleating Bcl10 polymerization, but are held in an autoinhibited state prior to stimulation. Here, we elucidate the structural basis for this autoinhibition by determining the structure of a region of CARD9 that includes an extensive interface between its caspase recruitment domain (CARD) and coiled-coil domain. We demonstrate, for both CARD9 and CARD11, that disruption of this interface leads to hyperactivation in cells and to the formation of Bcl10-templating filaments in vitro, illumi- nating the mechanism of action of numerous oncogenic mutations of CARD11. These structural insights enable us to characterize two similar, yet distinct, mechanisms by which autoinhibition is relieved in the course of canonical CARD9 or CARD11 activation. We also dissect the molecular determinants of helical template assembly by solving the structure of the CARD9 filament. Taken together, these findings delineate the structural mechanisms of inhibition and activation within this protein family. 1 Early Discovery Biochemistry Department, Genentech, South San Francisco, CA 94080, USA. 2 Stowers Institute for Medical Research, Kansas City, MO 64110, USA. 3 Biochemical and Cellular Pharmacology Department, Genentech, South San Francisco, CA 94080, USA. 4 Structural Biology Department, Genentech, South San Francisco, CA 94080, USA. 5 Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
    [Show full text]